Patrick Daly

DocwireNews

<p>Trials on first-line ibrutinib monotherapy in treatment-na&iuml;ve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have reported that patients who had an ibrutinib dose reduction due to adverse events (AEs) had efficacy outcomes similar to those who did not have a reduction.<p>However, researchers stated that current real-world data on ibrutinib dosing patterns and related outcomes are sparse. Investigators reviewed a US insurance claims database to identify real-world dosing patterns and time to next treatment (TTNT) in patients with a dose reduction versus those without. Their study was featured at the 2023 Society of Hematologic Oncology Annual Meeting.</p><p>According to the study&rsquo;s lead author, Mazyar Shadman, MD, patients with a dose reduction due to an AE actually had a longer TTNT compared with those who did not have a dose reduction. The authors did note their analysis could not establish causal associations between specific AEs and subsequent dose reductions.</p><h1>Ibrutinib Dose Reduction Improves Treatment Patterns in CLL</h1><p>Starting from February 2014, the analysis identified 658 patients treated with first-line single-agent ibrutinib 420 mg who had an AE during treatment and at least 90 days of follow-up after initiating treatment. Patients who discontinued ibrutinib were included in both groups. Time-varying Cox proportional hazards models were used to evaluate TTNT, defined as time from AE to first dose of another treatment or death.</p><p>After a recorded AE, 95 (14%) patients had an <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803460/" target="_blank" rel="noopener">ibrutinib</a> dose reduction and 563 (86%) did not. The study&rsquo;s authors identified the following treatment patterns for patients with or without a dose reduction:</p><table border="1">
<tbody>
<tr>
<td width="208"></td>
<td width="208">With dose reduction</td>
<td width="208">Without dose reduction</td>
</tr>
<tr>
<td width="208">Mean ibrutinib treatment duration</td>
<td width="208">922 days (median, 842)</td>
<td width="208">735 days (median, 606)</td>
</tr>
<tr>
<td width="208">Mean time to first AE</td>
<td width="208">161 days (median, 51)</td>
<td width="208">227 days (median, 119)</td>
</tr>
<tr>
<td width="208">Mean time from AE to end of therapy</td>
<td width="208">760 days (median, 725)</td>
<td width="208">508 days (median, 352)</td>
</tr>
</tbody>
</table><p>&nbsp;</p><p>Next treatment or death was less common in patients with a dose reduction (31%) versus patients without (39%), and the median TTNT was 59.5 months versus 30.6 months, respectively (unadjusted hazard ratio [HR], 0.56; <em>P</em>=.003; adjusted HR, 0.62; <em>P</em>=.017). Authors stated that patterns were similar between cardiac and noncardiac AE subgroups.</p><p>&ldquo;Using TTNT as a marker for disease progression,&rdquo; the report concluded, &ldquo;these findings suggest that ibrutinib dose reduction can be an effective strategy to manage adverse events while delaying disease progression.&rdquo;</p><p><strong>Related: <a href="https://docwirenews.com/post/venetoclax-efficacy-in-patients-with-cll-who-relapsed-after-hsct">Venetoclax Efficacy in Patients With CLL Who Relapsed After HSCT</a></strong></p></p>


Katie Kosko

Study Links Body Composition to Trastuzumab Deruxtecan Dosing, Toxicity

HER2 Breast Cancer

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Latest News

Real-world Outcomes of Ibrutinib Dose Reduction Versus No Reduction After AEs

SOHO 2023

Real-world patients with ibrutinib dose reductions after AEs had longer treatment durations and similar efficacy outcomes compared with those without reductions.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe